Symlin Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus.

Next Previous
Trial Profile

Symlin Dose Escalation Efficacy vs. Conventional Therapy in Type 2 Diabetes Mellitus.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 18 Aug 2012

At a glance

  • Drugs Pramlintide (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use

    • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 16 Oct 2011 Planned End Date changed from 1 May 2012 to 1 Apr 2012 as reported by ClinicalTrials.gov.
    • 16 Oct 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top